• 한국균학회지
• /
• 제19권4호
• /
• pp.258-265
• /
• 1991

담자균효모 Leucosporidium scottii, Leucosporidium fellii, Leucosporidium lari-marini, Rhodosporidium fluviale의 ubiuqinone계를 고속액체크로마토그래피에 의해 결정하였다. Leucosporidium scottii 균주는 교배형 또는 self-sporulating 형에 관계없이 Q-9 또는 Q-10계를 가지고 있었다. 특히 동일 균주에서도 ubiquinone계의 변이가 관찰되었다. 이는 분류지표로서 중요시 되는 ubiquinone계의 재평가를 시사하는 새로운 사실로 간주된다. Leucosporidium fellii는 Q-9, Leucosporidium lari-marini는 Q-8, Rhodosporidium fuviale는 Q-10을 함유하고 있었다. L. lari-marini의 분류학적 위치는 다각적 연구에 기초하여 해명되어야 한다.

• Applied Biological Chemistry
• /
• 제34권1호
• /
• pp.43-48
• /
• 1991

Menaquinone과 비슷한 구조로써 새로운 quinoline 화합물들은 design하고 합성하여 submitochondria를 이용하여 생리활성을 검정하였다. NADH-ubiquinone oxidoreductase를 저해하는 생리활성은 주로 친유성 부분인 측쇄의 길이에 의존되었다. Quinoline핵의 3위치는 methyl group일 때가 가장 높은 저해활성을 나타냈다.

• Applied Biological Chemistry
• /
• 제33권3호
• /
• pp.264-267
• /
• 1990

호습쇄의 NADH-ubiquinone oxidoreductase를 강력히 저해하는 합성 piericidin유사체로써 hydroxypyridine 및 hyoxyquinoline 유도체들이 전반적으로 좋은 살균활성을 보였다. 특히, hydroxypyfidine 유도체들은 벼도열병(Pyricularia oryzae)과 보리흰가루병(Erysiphe graminis)에 대해서 높은 살균활성을 나타했다.

• 미생물학회지
• /
• 제32권4호
• /
• pp.252-257
• /
• 1994

황화수소 산화세균인 Thiobacillus sp.를 전남 화순의 폐탄광수에서 분리하였다. 분리된 균주는 그람음성의 운동성이 있고, 포자를 형성하는 간균이었으며, 환원된 무기 황화합물을 산화하여 에너지원으로 사용하는 호기성 통성 화학합성 영양균이었다. 분리균주는 thiosulfate를 첨가한 기본배지에서 유기물을 동화하며 성장하였고, 에너지원으로 사용된 thiosulfate는 32mM 이상의 농도에서는 오히려 기질억제 인자로 작용하여 균의 성장을 억제하였다. 최적 thiosulfate 농도는 32mM이었다. DNA의 G+C 함량은 65.0mol%이고, 세포내 주요 지방산중 비순산화 지방산은 16:1+7$_{cyc}$, 16:0과 수산화 지방산은 3-OH 12:0을 가지며, $C_{18}$의 미동정 가지형의 지방산도 포함하고 있었다. Ubiquinone system은 Q-9을 가지고 있었다. 위와 같은 생리생화학적 특성 결과로부터, 본 분리균주는 Thiobacillus sp. iw.의 새로운 종으로 판단하였다.

• 미생물학회지
• /
• 제29권4호
• /
• pp.250-257
• /
• 1991

An obligate methanol-oxidizing bacterium, Methylobacillus sp. strain SK1, which grows only on methanol was isolated from soil. The isolate was nonmotile Gram-negtive rod. It does not have internal membrane system. The colonies were small, whitish-yellow, and smooth. The guanine plus cytosine content of the DNA was 48 mol%. Cellular fatty acids consisted predominantly of large amounts of straight-chain saturated $C_{16:0}$ acid and unsaturated $C_{16:1}$ acid. The major ubiquinone was Q-8, and Q-10 was present as minor component. The cell was obligately aerobic and exhibited catalase, but no oxidase, activity. Poly-.betha.-hydroxybutyrate, endospores, or cysts were not observed. the isolate could grow only on methanol in mineral medium. Growth factors were not required. The isolate was unable to use methane, formaldehyde, formate, methylamine, and several other organic compounds tested as a sole source of carbon and energy. Growth was optimal at 35.deg.C and pH 7.5. It could not grow at 42.deg.C. The doubling time was 1.2h at 30.deg.C when grown with 1.0%(v/v) methanol. The growth was not affected by antibiotics inhibiting cell wall synthesis and carbon monoxide but was completely suppressed by those inhibiting protein synthesis. Methanol was found to be assimilated through the ribulose monophosphate pathway. Cytochromes of b-, c-, and o- types were found. Cell-free extracts contained a phenazine methosulfate-linked methanol dehydrogenase activity, which required ammonium ions as an activator. Cells harvested after the late exponential phase seemed to contain blue protein.ein.

• Advances in Traditional Medicine
• /
• 제10권4호
• /
• pp.239-253
• /
• 2010

Coenzyme $Q_{10}$ ($CoQ_{10}$, or ubiquinone) is an electron carrier of the mitochondrial respiratory chain (electron transport chain) with antioxidant properties. In view of the involvement of $CoQ_{10}$ in oxidative phosphorylation and cellular antioxidant protection a deficiency in this quinone would be expected to contribute to disease pathophysiology by causing a failure in energy metabolism and antioxidant status. Indeed, a deficit in $CoQ_{10}$ status has been determined in a number of neuromuscular and neurodegenerative disorders. Primary disorders of $CoQ_{10}$ biosynthesis are potentially treatable conditions and therefore a high degree of clinical awareness about this condition is essential. A secondary loss of $CoQ_{10}$ status following HMG-CoA reductase inhibitor (statins) treatment has been implicated in the pathophysiology of the myotoxicity associated with this pharmacotherapy. $CoQ_{10}$ and its analogue, idebenone, have been widely used in the treatment of neurodegenerative and neuromuscular disorders. These compounds could potentially play a role in the treatment of mitochondrial disorders, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, and other conditions which have been linked to mitochondrial dysfunction. This article reviews the physiological roles of $CoQ_{10}$, as well as the rationale and the role in clinical practice of $CoQ_{10}$ supplementation in different neurological diseases, from primary $CoQ_{10}$ deficiency to neurodegenerative disorders. These will help in future for treatment of patients suffering from neurodegenerative disease.